Biotechnology

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

* SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. * The parti...

2024-12-23 09:00 1149

Macrogen Consortium win tender for National Bio Big Data Project

Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and arra...

2024-12-23 08:00 1406

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

* Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive$6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. * Patients with relapsed/refractory follicular lympho...

2024-12-19 23:00 1505

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 /PRNewswire/ -- Prenetics' (NASDAQ:PRE) IM8, a...

2024-12-19 21:30 1831

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South,Belgium, facilita...

2024-12-19 17:02 1682

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid bi...

2024-12-19 01:00 1810

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Highlights: * IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 * The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies,...

2024-12-18 10:59 1596

Amai Proteins succesfully completed world's first human clinical trial on effects of sweet proteins, with sweelin®

REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ -- Amai Proteins , a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their ...

2024-12-17 09:00 999

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and  over 70% of patients in TANDEM (Fixed Do...

2024-12-16 22:08 1490

World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets

KOTA KINABALU, Malaysia, Dec. 16, 2024 /PRNewswire/ -- A groundbreaking new book by Professor Dr.Mike Chan, "STEM CELLS, PEPTIDES & IMMUNOTHERAPY: Handbook on Regenerative Medicine for Animals," introduces revolutionary ...

2024-12-16 22:00 2158

HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea

SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique globalclinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundan...

2024-12-16 10:30 1571

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

SAN FRANCISCO and SUZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-12-16 07:55 2143

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC...

2024-12-13 10:35 2135

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 1464

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

* ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer withESR1 mutations, aiming to delay disease progression. * The study was presented by the Menarini Group and MEDSIR at the San Ant...

2024-12-12 18:07 1502

CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion

* Non-dilutive growth financing of up to US$50 million, with a synthetic royalty feature, and availability linked to achievement of certain sales milestones * Proceeds from the financing will fund Human Investments Ltd.'s expansion of Motiva® devices inAsia * Transaction highlights R-Bridge...

2024-12-12 14:14 2813

Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...

2024-12-12 11:48 1777

Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion

HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch inBoston ,USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the ...

2024-12-11 14:44 2183

Call for Application for 2025 Tsinghua Amgen Scholars Program

BEIJING, Dec. 11, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...

2024-12-11 14:33 2231

2024 PHBS-CJBS Global Pitch Competition Grand Final Held

SHENZHEN, China, Dec. 11, 2024 /PRNewswire/ -- The 2024 PHBS-CJBS Global Pitch Competition, jointly hosted by Peking University HSBC Business School (PHBS) and Cambridge Judge Business School (CJBS), concluded with its grand final on December 5th at PHBS in Shenzhen, China. During the finals...

2024-12-11 12:29 1340
12345 ... 180